Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine.
The investigational vaccine, based on the company’s PlaCCine technology, targets the SARS-CoV-2 Omicron XBB1.5 spike antigen as a seasonal Covid-19 vaccine.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial involved 24 healthy volunteers who had been vaccinated previously against the Omicron XBB1.5 variant.
IMNN-101 was given as a single-dose vaccine, which was found to be well-tolerated and safe, without any serious adverse effects.
The vaccine “induced” a persistent two- to four-fold increase in serum neutralising antibody titers through week 4 from baseline, with titers continuing to rise between week 2 and 4.
The immune response against the XBB1.5 variant and several newer variants demonstrated the “cross-reactivity” of the vaccine.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSubjects in the trial had high baseline immune characteristics due to previous infection and several vaccinations against Covid-19, which was evident from the viral nucleocapsid antigen rise during the trial, stated the company.
Additionally, modest increases in T cell responses were noted among the trial subjects.
Imunon CEO and president Stacy Lindborg said: “These data demonstrate that our first-in-human vaccine based on our PlaCCine platform is safe and immunogenic and is well-suited to developing vaccine candidates for protecting the population against a potential future exposure to a pathogen or controlling a rising pathogen.”
The Phase I data aligns with previous preclinical findings, showing over 95% protection in non-human primates, comparable to mRNA vaccines.
The technology platform involves a DNA plasmid that regulates the primary pathogen antigens’ expression, coupled with a synthetic DNA delivery system.
In February 2024, the company began enrolling subjects at Memorial Sloan Kettering Cancer Center for a Phase I/II trial of DNA-based interleukin-12 (IL-12) immunotherapy, IMNN-001, in individuals with advanced ovarian cancer.
